Trademark Details For VYDAPTIV (Serial Number 88664224)

Therapeutic protein molecules used in the manufacture of pharmaceutics and biologically-derived medical preparations; all the foregoing to exclude such molecules relating to antibiotics and pharmaceutical preparations for the treatment and prophylaxis of infectious diseases;

Pharmaceutical preparations containing polypeptides, antibodies, or antibody derivatives for the treatment and prophylaxis of cancer and immune system diseases and disorders, and autoimmune system diseases, namely, neurological and neuromuscular diseases and disorders, gastrointestinal diseases, nervous system diseases and disorders, respiratory system diseases, lymphatic system diseases, primary and secondary immunodeficiency disorders, genetic autoimmune diseases, severe combined immunodeficiency diseases, immune complex diseases, and immunodeficiency diseases, including, allergies, asthma, diabetes, rheumatoid arthritis, multiple sclerosis, lupus, Hashimoto's, inflammatory bowel disease, Guillain-Barre, psoriasis, chronic inflammatory demyelinating polyneuropathy (CIPD), Graves' disease, myasthenia gravis, and transplant rejection diseases, and blood disorders, all of the foregoing to exclude antibiotics and pharmaceutical preparations for the treatment and prophylaxis of infectious diseases;

Research and development in the pharmaceutical and biotechnology fields relating to polypeptides, antibodies or antibody derivatives, in relation to the treatment and prophylaxis of cancer, immune system diseases and disorders, and autoimmune system diseases, namely, neurological and neuromuscular diseases and disorders, gastrointestinal diseases, nervous system diseases and disorders, respiratory system diseases, lymphatic system diseases, primary and secondary immunodeficiency disorders, genetic autoimmune diseases, severe combined immunodeficiency diseases, immune complex diseases, and immunodeficiency diseases, including, allergies, asthma, diabetes, rheumatoid arthritis, multiple sclerosis, lupus, Hashimoto's, inflammatory bowel disease, Guillain-Barre, psoriasis, chronic inflammatory demyelinating polyneuropathy (CIPD), Graves' disease, myasthenia gravis, and transplant rejection diseases, and blood disorders, all of the foregoing to exclude research and development in relation to antibiotics and the treatment and prophylaxis of infectious diseases;